Month: September 2024

Reference is made to the notice on 25 September 2024 regarding issue of Tranche 1 shares of the private placement completed on 16 September 2024. The private placement consisted of two tranches, with total gross proceeds amounting to NOK 70 million. The share capital increase related to the Tranche 1 shares has been registered and the shares will be delivered soonest. The Tranche 1 shares will be delivered on a separate and non-tradable ISIN, pending publication by the Company of a prospectus approved by the Norwegian Financial Supervisory Authority. Following the issue, the Company’s share capital will be NOK 66,056,228.10 divided into 440,374,854 shares, each with a nominal value of NOK 0.15. For further information contact:Marianne Bøe, Investor RelationsE-mail: marianne.boe@idexbiometrics.comTel: +47 918 00186 About IDEX BiometricsIDEX...

Achieved first lithium production, advancing Volt Lithium’s commitment to securing a North American supply of lithium Commence cash generation by the end of 2024 with the goal to be cash flow positive in the first half of 2025 Poised for long-term cost-effective growth underpinned by one of the lowest DLE operating cost structures in North AmericaCALGARY, Alberta, Sept. 26, 2024 (GLOBE NEWSWIRE) — Volt Lithium Corp. (TSXV: VLT | OTCQB: VLTLF I FSE: I2D) (“Volt” or the “Company“) announces that the Company has commenced U.S. field operations in the Permian Basin in Texas, achieving the significant milestone of first lithium production. “Achieving first lithium production establishes Volt as a leader in direct lithium extraction from North American oilfield brines and marks the Company’s strategic shift...

PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON THE MICROTUBULE PROGRAM AB8939 AND IN PARTICULAR THE ABILITY OF AB8939 TO GENERATE RESPONSE ON MECOM REARRANGEMENT Paris, 26 September 2024, 8.30am CET AB Science SA (Euronext – FR0010557264 – AB) today provides an update on the microtubule program AB8939 and in particular the ability of AB8939 to generate response on MECOM rearrangement. AB8939 is a novel microtubule destabilizer currently evaluated in phase 1 clinical trial (study AB18001, NCT05211570) in patients with refractory and relapsed acute myeloid leukemia (AML). The phase 1 clinical trial of AB8939 completed its first step, consisting in determining the maximum tolerated dose following 3 consecutive days of AB8939 treatment, and was authorized to proceed with the next step, consisting in determining the maximum tolerated...

Paris, 26th of September 2024 — Virtune, a Swedish regulated digital asset manager and issuer of crypto Exchange Traded Products (ETPs) based in Stockholm, Sweden, announces its expansion into France through the listing of its Virtune Staked Solana ETP on Euronext Paris. With strong traction and consistent inflows in the Nordic regions driven by increasing interest and crypto adoption, expanding into France is a strategic milestone for Virtune. Virtune has since its inception in May 2023 been growing rapidly in the Nordics where it has listed a total of 12 products and reached more than 31 000 investors in its products in just about one year. The key success factors have been an educational focus, a transparent market approach and through its regulated status. This move not only addresses growing investor enthusiasm but also enhances our...

Sampo plc, stock exchange release, 26 September 2024 at 8:30 am EEST Sampo plc’s share buybacks 25 September 2024 On 25 September 2024, Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI4000552500) as follows:                Sampo plc’s share buybacks Aggregated daily volume (in number of shares) Daily weighted average price of the purchased shares* Market (MIC Code)  4,141 41.77 AQEU          40,636 41.74 CEUX  1,326 41.78 TQEX  45,119 41.73 XHELTOTAL 91,222 41.73  *rounded to two decimals                 On 17 June 2024, Sampo announced a share buyback programme of up to a maximum of EUR 400 million in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052. On 16 September 2024, the Board of Directors...

Enables French retail investors to buy securities under preferential tax conditionsDijon, France Sept 26, 2024 — Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company developing medicines for emergency situations harnessing its award-winning needle-free auto-injector ZENEO®, today confirms its eligibility for PEA-PME, a French government investment scheme which enables retail investors to acquire a portfolio of European securities whilst benefiting from preferential tax conditions. This framework aims to diversify funding resources available to small and medium sized enterprises (SMEs) and create a new financing tool, thus channeling some savings into the real economy. Tax advantages offered by PEA-PME (Plan d’Épargne en Actions – Petites et Moyennes Entreprises or Share Savings Plan – Small and Mid-sized...

(Bergen, 26. september 2024) I dag arrangerer Mowi sin kapitalmarkedsdag hvor selskapet presenterer planer om videre volumvekst for havbruksvirksomheten fra 500 000 tonn til 600 000 tonn, samt ytterligere kostnadsforbedringer i størrelsesorden 300-400 millioner euro. Verdens største oppdretter og videreforedler av laks, Mowi, arrangerer i dag sin kapitalmarkedsdag på Fosen i Trøndelag. Der presenterer selskapet sin strategi og planer de neste årene for å styrke posisjonen som ledende i næringen. – Etter å ha nådd en milepæl på 500 000 tonn laks i 2024, vender vi nå blikket mot neste milepæl på 600 000 tonn som vi tar sikte på å nå i 2029. Dette vil vi gjøre ved å ta i bruk ledig kapasitet, samt å øke produktiviteten og biologiske prestasjoner på eksisterende produksjon gjennom vår postsmoltsatsning, sier konsernsjef Ivan Vindheim. I tillegg...